Recent News

• 04.08.2025 - Enanta Pharmaceuticals Announces Respiratory Syncytial Virus Data Presentation at ESCMID Global 2025
• 04.08.2025 - Enanta Pharmaceuticals Announces Respiratory Syncytial Virus Data Presentation at ESCMID Global 2025
• 03.27.2025 - H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference
• 03.27.2025 - H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference
• 03.17.2025 - Enanta Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference
• 03.17.2025 - Enanta Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference
• 03.13.2025 - 2025 Annual Meeting
• 03.13.2025 - 2025 Annual Meeting
• 03.12.2025 - Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus Program at the 13th International RSV Symposium
• 03.12.2025 - Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus Program at the 13th International RSV Symposium

Recent Filings

• 03.17.2025 - 8-K Current report
• 03.14.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.14.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.14.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.14.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.14.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.14.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.14.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.14.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.14.2025 - 4 Statement of changes in beneficial ownership of securities